^
Association details:
| Biomarker: | FGFR2 fusion |
|---|---|
| Cancer: | Colon Cancer |
| Drug: | zoligratinib (Debio 1347) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion
Excerpt:
Partial responses were observed in 3 pts harboring an FGFR2 fusion: 1 out of 2 colon cancer…Debio 1347 at the recommended dose of 80 mg qd was generally well tolerated and showed signs of activity in solid tumors harboring an FGFR fusion.
DOI:
10.1200/JCO.2020.38.15_suppl.3603
